{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:34:35Z","timestamp":1792722875782,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this meta-analysis is to evaluate the role of high-intensity statin pretreatment on coronary microvascular dysfunction in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Cochrane, and Embase were searched. This meta-analysis selection included randomized controlled trials (RCTs), involving high-intensity statin pretreatment as active treatment, and measurement of thrombolysis in myocardial infarction (TIMI), myocardial blush grade (MBG) or index of microvascular resistance (IMR) in coronary heart disease (CHD) patients undergoing PCI. I\n                      <jats:sup>2<\/jats:sup>\n                      test was used to evaluate heterogeneity. Pooled effects of continuous variables were reported as Standard mean difference (SMD) and 95% confidence intervals (CI). Pooled effects of discontinuous variables were reported as risk ratios (RR) and 95% confidence intervals (CI). Random-effect or fix-effect meta-analyses were performed. The Benefit was further examined based on clinical characteristics including diagnosis and statin type by using subgroup analyses. Publication bias was examined by quantitative Egger\u2019s test and funnel plot. We performed sensitivity analyses to examine the robustness of pooled effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty RCTs were enrolled. The data on TIMI\u2009&lt;\u20093 was reported in 18 studies. Comparing with non-high-intensity statin, high-intensity statin pretreatment significantly improved TIMI after PCI (RR\u2009=\u20090.62, 95%CI: 0.50 to 0.78,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The data on MBG\u2009&lt;\u20092 was reported in 3 studies. The rate of MBG\u2009&lt;\u20092 was not different between groups (RR\u2009=\u20091.29, 95% CI: 0.87 to 1.93,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.21). The data on IMR was reported in 2 studies. High-dose statin pretreatment significantly improved IMR after PCI comparing with non-high-dose statin (SMD\u2009=\u2009-0.94, 95% CI: -1.47 to -0.42,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0004). There were no significant between-subgroup differences in subgroups based on statin type and diagnosis. Publication bias was not indicated by using quantitative Egger\u2019s test (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.97) and funnel plot. Sensitivity analyses confirmed the robustness of these findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Comparing with non-high-intensity statin, high-intensity statin pretreatment significantly improved TIMI and IMR after PCI. In the future, RCTs with high quality and large samples are needed to test these endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-023-03402-9","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T11:02:34Z","timestamp":1690196554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A systematic review and meta-analysis of the effect of high-intensity statin on coronary microvascular dysfunction"],"prefix":"10.1186","volume":"23","author":[{"given":"Bihan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"3402_CR1","unstructured":"Members WC, Lawton JS, Tamis-Holland JE, et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol. 2022;79(2):e21\u2013e129."},{"issue":"10","key":"3402_CR2","first-page":"66","volume":"47","author":"Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology","year":"2019","unstructured":"Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Zhonghua xin xue guan bing za zhi. 2019;47(10):66.","journal-title":"Zhonghua xin xue guan bing za zhi"},{"issue":"1","key":"3402_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ehjqcco\/qcv010","volume":"1","author":"SV Arnold","year":"2015","unstructured":"Arnold SV, Jang JS, Tang F, et al. Prediction of residual angina after percutaneous coronary intervention. Eur Heart J Qual Care Clin Outcomes. 2015;1(1):23\u201330.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"4","key":"3402_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cvr\/cvz301","volume":"116","author":"LSF Konijnenberg","year":"2020","unstructured":"Konijnenberg LSF, Damman P, Duncker DJ, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res. 2020;116(4):787\u2013805.","journal-title":"Cardiovasc Res"},{"issue":"24","key":"3402_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","volume":"282","author":"JC LaRosa","year":"1999","unstructured":"LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340\u20136.","journal-title":"JAMA"},{"issue":"4","key":"3402_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1161\/01.CIR.0000153810.81187.7D","volume":"111","author":"V Sanguigni","year":"2005","unstructured":"Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111(4):412\u20139.","journal-title":"Circulation"},{"issue":"21_suppl_1","key":"3402_CR7","doi-asserted-by":"publisher","first-page":"II-18","DOI":"10.1161\/01.CIR.0000129505.34151.23","volume":"109","author":"U Sch\u00f6nbeck","year":"2004","unstructured":"Sch\u00f6nbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21_suppl_1):II-18\u2013II\u221226.","journal-title":"Circulation"},{"issue":"8","key":"3402_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2005.05.086","volume":"46","author":"KK Ray","year":"2005","unstructured":"Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46(8):1425\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3402_CR9","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/01.RES.0000099503.13312.7B","volume":"93","author":"S Wassmann","year":"2003","unstructured":"Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003;93(9):e98\u2013103.","journal-title":"Circ Res"},{"issue":"4","key":"3402_CR10","first-page":"355","volume":"10","author":"GX He","year":"2013","unstructured":"He GX, Tan W. High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention. J Geriatr Cardiol. 2013;10(4):355.","journal-title":"J Geriatr Cardiol"},{"issue":"6","key":"3402_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ahj.2011.08.011","volume":"162","author":"JY Hahn","year":"2011","unstructured":"Hahn JY, Kim HJ, Choi YJ, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2011;162(6):1026\u201333.","journal-title":"Am Heart J"},{"issue":"1","key":"3402_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2014.03.059","volume":"114","author":"YG Ko","year":"2014","unstructured":"Ko YG, Won H, Shin DH, et al. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY study). Am J Cardiol. 2014;114(1):29\u201335.","journal-title":"Am J Cardiol"},{"issue":"2","key":"3402_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87\u2013165.","journal-title":"Eur Heart J"},{"issue":"12","key":"3402_CR14","doi-asserted-by":"publisher","first-page":"e005361","DOI":"10.1161\/CIRCINTERVENTIONS.117.005361","volume":"10","author":"WF Fearon","year":"2017","unstructured":"Fearon WF, Kobayashi Y. Invasive assessment of the coronary microvasculature: the index of microcirculatory resistance. Circ Cardiovasc Interv. 2017;10(12):e005361.","journal-title":"Circ Cardiovasc Interv"},{"key":"3402_CR15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Dondo Higgins","year":"2011","unstructured":"Dondo Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7568","key":"3402_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","volume":"333","author":"J Lau","year":"2006","unstructured":"Lau J, Ioannidis JPA, Terrin N, et al. The case of the misleading funnel plot. BMJ. 2006;333(7568):597\u2013600.","journal-title":"BMJ"},{"issue":"2","key":"3402_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","volume":"7","author":"M Richardson","year":"2019","unstructured":"Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7(2):192\u20138.","journal-title":"Clin Epidemiol Glob Health"},{"issue":"5","key":"3402_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ccd.23449","volume":"80","author":"S Post","year":"2012","unstructured":"Post S, Post MC, van den Branden BJ, et al. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv. 2012;80(5):756\u201365.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"10","key":"3402_CR19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00380-015-0773-y","volume":"31","author":"M Shimomura","year":"2016","unstructured":"Shimomura M, Oyama J, Takeuchi M, et al. Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial). Heart Vessels. 2016;31(10):1583\u20139.","journal-title":"Heart Vessels"},{"issue":"3","key":"3402_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clinthera.2013.01.009","volume":"35","author":"H Liu","year":"2013","unstructured":"Liu H, Yang Y, Yang S, et al. Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study. Clin Ther. 2013;35(3):261\u201372.","journal-title":"Clin Ther"},{"issue":"1","key":"3402_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3892\/etm.2016.3910","volume":"13","author":"W Liu","year":"2017","unstructured":"Liu W, Zou Z, Jiang H, et al. Clinical effect of preoperative high-dose atorvastatin against no-reflow after PCI. Exp Ther Med. 2017;13(1):97\u2013102.","journal-title":"Exp Ther Med"},{"issue":"4","key":"3402_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4070\/kcj.2016.46.4.472","volume":"46","author":"BK Lee","year":"2016","unstructured":"Lee BK, Koo BK, Nam CW, et al. Does pre-treatment with high dose atorvastatin prevent microvascular dysfunction after percutaneous coronary intervention in patients with acute coronary syndrome? Korean Circ J. 2016;46(4):472\u201380.","journal-title":"Korean Circ J"},{"issue":"3","key":"3402_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000356434","volume":"127","author":"Q Su","year":"2014","unstructured":"Su Q, Li L, Liu Y, et al. Effect of intensive atorvastatin therapy on periprocedural PDCD4 expression in CD4+ T lymphocytes of patients with unstable angina undergoing percutaneous coronary intervention. Cardiology. 2014;127(3):169\u201375.","journal-title":"Cardiology"},{"issue":"4","key":"3402_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3346\/jkms.2015.30.4.435","volume":"30","author":"EK Kim","year":"2015","unstructured":"Kim EK, Hahn JY, Song YB, et al. Effects of high-dose atorvastatin pretreatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study. J Korean Med Sci. 2015;30(4):435\u201341.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"3402_CR25","first-page":"332","volume":"3","author":"JS Kim","year":"2010","unstructured":"Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC: Cardiovasc Interv. 2010;3(3):332\u20139.","journal-title":"JACC: Cardiovasc Interv"},{"issue":"9","key":"3402_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/1060028016654722","volume":"50","author":"Z Liu","year":"2016","unstructured":"Liu Z, Joerg H, Hao H, et al. Efficacy of high-intensity atorvastatin for Asian patients undergoing percutaneous coronary intervention. Ann Pharmacother. 2016;50(9):725\u201333.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3402_CR27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10753-015-0116-2","volume":"38","author":"J Yang","year":"2015","unstructured":"Yang J, Liu C, Zhang L, et al. Intensive atorvastatin therapy attenuates the inflammatory responses in monocytes of patients with unstable angina undergoing percutaneous coronary intervention via peroxisome proliferator-activated receptor \u03b3 activation. Inflammation. 2015;38(4):1415\u201323.","journal-title":"Inflammation"},{"issue":"6","key":"3402_CR28","first-page":"659","volume":"122","author":"X Jia","year":"2009","unstructured":"Jia X, Fu X, Zhang J, et al. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J. 2009;122(6):659\u201364.","journal-title":"Chin Med J"},{"issue":"6","key":"3402_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.14503\/THIJ-14-4891","volume":"42","author":"M Shehata","year":"2015","unstructured":"Shehata M, Fayez G, Nassar A. Intensive statin therapy in NSTE-ACS patients undergoing PCI: clinical and biochemical effects. Tex Heart Inst J. 2015;42(6):528\u201336.","journal-title":"Tex Heart Inst J"},{"issue":"6","key":"3402_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/joic.12427","volume":"30","author":"M Shehata","year":"2017","unstructured":"Shehata M, Samir A, Dardiri M. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. J Interv Cardiol. 2017;30(6):514\u201321.","journal-title":"J Interv Cardiol"},{"issue":"3","key":"3402_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/FJC.0b013e31829be05b","volume":"62","author":"M Chen","year":"2013","unstructured":"Chen M, Li H, Wang Y. Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals. J Cardiovasc Pharmacol. 2013;62(3):320\u20134.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"3402_CR32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.arcmed.2018.10.006","volume":"49","author":"RC Garc\u00eda-M\u00e9ndez","year":"2018","unstructured":"Garc\u00eda-M\u00e9ndez RC, Almeida-Gutierrez E, Serrano-Cuevas L, et al. Reduction of no reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute ST Myocardial Infarction. Arch Med Res. 2018;49(8):620\u20139.","journal-title":"Arch Med Res"},{"issue":"12","key":"3402_CR33","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.amjcard.2013.02.018","volume":"111","author":"H Takano","year":"2013","unstructured":"Takano H, Ohba T, Yamamoto E, et al. Usefulness of rosuvastatin to prevent periprocedural myocardial injury in patients undergoing elective coronary intervention. Am J Cardiol. 2013;111(12):1688\u201393.","journal-title":"Am J Cardiol"},{"issue":"6","key":"3402_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00395-019-0756-8","volume":"114","author":"G Heusch","year":"2019","unstructured":"Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol. 2019;114(6):45.","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"3402_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407.","journal-title":"Eur Heart J"},{"key":"3402_CR36","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.12659\/MSM.911921","volume":"24","author":"Y Xiao","year":"2018","unstructured":"Xiao Y, He S, Zhang Z, et al. Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies. Med Sci Monit. 2018;24:9166.","journal-title":"Med Sci Monit"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03402-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T11:03:29Z","timestamp":1690196609000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03402-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03402-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2785896\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"370"}}